BioNTech SE (BNTX) Form 6-K — Oct 26, 2026
BioNTech and Bristol Myers Squibb announced first data from the Phase 2 ROSETTA Lung-107 trial of pumitamig (BNT327/BMS986545) plus docetaxel in second-line metastatic NSCLC, presented at ESMO 2026. Among 30 efficacy-evaluable patients, the combination achieved a confirmed objective response rate of 36.7% and disease control rate of 90.0%, with median progression-free survival of 6.9 months versus roughly 3.6-3.9 months historically for standard-of-care docetaxel. Responses were consistent across PD-L1 expression levels and histologies, and safety was manageable with no new signals or treatment-related deaths.
Key figures
- Grade3 trae rate
- 18.0%
- Treated patients
- 50
- Median pfs months
- 6.9
- Six month pfs rate
- 63.3%
- Disease control rate
- 90.0%
- Median followup weeks
- 12.2
- Efficacy evaluable patients
- 30
- Treatment discontinuation rate
- 8.0%
- Confirmed objective response rate
- 36.7%
- Standard of care docetaxel median pfs
- approximately 3.6 months (non-squamous) / 3.9 months (squamous)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.